Effectiveness of Proton-Pump Inhibitors in Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials

Fei Yu, Qihui Huang, Yousheng Ye and Lin Zhang*

The First People’s Hospital of Hefei, Hefei, China

Background: Although several randomized controlled trials (RCTs) have been published in recent years, the role of proton-pump inhibitors (PPI) in patients with chronic obstructive pulmonary disease (COPD) remains controversial. This preliminary meta-analysis was conducted to evaluate the clinical efficacy of PPI in patients with COPD.

Methods: RCTs related to PPI in the treatment of patients with a definite diagnosis of COPD were enrolled in this meta-analysis. PubMed, Embase, Cochrane Library, CNKI, Wanfang and VIP databases were retrieved to identify eligible studies from database establishment to September 22, 2021. Two researchers independently screened the articles, extracted the data and evaluated the risk of bias in the included studies independently. The study complied with PRISMA 2020 guideline for this study. The meta-analysis was performed using RevMan 5.3. Heterogeneity among studies was tested using the \( I^2 \) test. The results were presented as risk ratios (RRs) with 95% confidence intervals (CIs).

Results: A total of 15 RCTs, including 1,684 patients, were enrolled. The meta-analysis revealed that PPI plus conventional treatment was superior to conventional treatment with respect to the case fatality rate (RR = 0.30; 95% CI, 0.18–0.52; \( P < 0.001 \)), the incidence of gastrointestinal bleeding (RR = 0.23; 95% CI, 0.14–0.38; \( P < 0.001 \)), the incidence of other adverse reactions (RR = 0.33; 95% CI, 0.28–0.39; \( P < 0.001 \)) and the number of acute exacerbations [mean difference (MD) = −1.17; 95% CI, 1.75 to −0.60; \( P < 0.001 \)] in patients with COPD. No significant differences were found in clinical efficacy (RR = 1.08; 95% CI, 0.95–1.22; \( P = 0.25 \)), FEV1/FVC (MD = 3.94; 95% CI, −8.70 to 16.58; \( P = 0.54 \)) and nosocomial infection rate (RR = 1.31; 95% CI, 0.57–3.00; \( P = 0.52 \)) between the two groups.

Discussion: This comprehensive meta-analysis suggested that PPI treatment for COPD may reduce the case fatality rate, incidence of gastrointestinal bleeding and other adverse reactions and number of acute exacerbations. However, the present meta-analysis also has some limitations of the evidence, such as the high risk of bias of the included studies, and predominance of included studies from China, which may result in publication bias. Therefore, further large-scale RCTs are needed to confirm our findings.

Systematic Trial Registration: Identifier: CRD42022301304.

Keywords: proton pump inhibitors, chronic obstructive pulmonary disease, clinical efficacy, gastroesophageal reflux disease, meta-analysis
INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by persistent airflow limitation and dyspnoea. It is the third leading cause of death worldwide and causes a huge economic burden to society because of its chronic disease course, repeated acute exacerbations and effects on performing activities of daily living (1). Previous studies have shown that the prevalence of gastroesophageal reflux disease (GERD) in patients with COPD was higher than that in the normal population. GERD may cause acute exacerbation of COPD and is considered an independent risk factor for COPD death (2–4). COPD and GERD are mutually causal, forming a vicious circle, which seriously affects the quality of life (5). Proton-pump inhibitors (PPI) are the first-line drugs for the treatment of GERD. PPI therapy for patients with COPD complicated with GERD may reduce the number of acute exacerbations of COPD, thus delaying disease progression of the disease and improving clinical outcomes.

Thus, far, the pathogenesis of COPD remains unclear. Many patients with COPD complicated with GERD have not received formal diagnosis and treatment, and numerous GERD cases are asymptomatic. In addition, the systemic efficacy and mortality risk of PPI in patients with COPD are controversial. Herein, we conducted a comprehensive meta-analysis of randomized controlled trials (RCTs) to explore the clinical efficacy and safety of PPI therapy in patients with COPD.

METHODS

Eligibility Criteria

RCTs were strictly screened following the PICOS principle (participants, interventions, comparisons, outcomes and study design). The inclusion criteria were as follows: (1) the participants were diagnosed with COPD according to the COPD Global Initiative (GOLD guidelines) (6); (2) RCTs compared conventional treatment plus PPI treatment with conventional treatment alone, and (3) RCTs were included regardless of the absence or presence of blind. The exclusion criteria were as follows: (1) basic experiments, animal experiments, repeated publications, and documents that cannot extract key information such as intervention measures and outcome indicators, and (2) the articles that have obvious experimental design errors or data errors.

Information Sources and Search Strategy

The search conducted using a combination of subject terms and entry terms as follows: Pulmonary Disease, Chronic Obstructive, Chronic Obstructive Lung Disease, Chronic Obstructive Pulmonary Diseases, COAD, COPD, Chronic Obstructive Airway Disease, Chronic Obstructive Pulmonary Disease, Airflow Obstruction, Chronic, Airflow Obstructions, Chronic, Chronic Airflow Obstructions, Chronic Airflow Obstruction, Proton-pump Inhibitors, Inhibitors, Proton-pump, Proton-pump Inhibitor, Inhibitor, Proton-pump, Pump Inhibitor, Proton, Omeprazole, Esomeprazole, Esomeprazole, Rabeprazole, Pantoprazole, Ilaprazole, Lansoprazole, etc. Moreover, the references of the included articles were screened to determine appropriate related studies.

Data Collection and Quality Assessment

Two researchers (Fei Yu and Qi-hui Huang) screened the articles and extracted data independently according to the PRISMA 2020 recommendations (7). Discussion or third-party negotiation was conducted in case of a dispute. If necessary, the authors of the enrolled studies were contacted by email or telephone to obtain information that was not presented in the article but was important to the present study. The following details were extracted from each study: basic information of the studies, baseline characteristics of the research object, test grouping, specific treatment measures, key elements of the bias risk assessment, outcome indicators and specific data.

In this study, the primary outcome indicators were the case fatality rate and clinical efficacy. The secondary outcome indicators include forced expiratory volume in 1/forced vital capacity (FEV1/FVC), gastrointestinal bleeding, other adverse reactions, nosocomial infections and number of acute exacerbations. Two investigators independently (Fei Yu and Qi-hui Huang) evaluated the risk of bias in the included studies and cross-checked the results. The second version of the Cochrane tool for assessing RoB in RCTs (RoB2) was used (8). This tool consists of the following five parts: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in the measurement of the outcomes and bias in the selection of the reported result. The risk levels are classified as low risk of bias, some concerns and high risk of bias. In addition, the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) was used to rate the level of evidence of the outcomes obtained in this study (9). Assessment of the quality of evidence considers five aspects: limitations, inconsistencies, indirectness, inaccuracy and publication bias.

Statistical Analyses

RevMan 5.3 was used for statistical analysis. Results of the meta-analysis of categorical variables were presented as Risk Ratios (RRs) with 95% confidence intervals (CIs), and the results of the analysis of continuous variables were presented as mean difference (MD) with 95% CIs. The results were expressed by P-value, and P < 0.05 indicated the difference between two intervention measures. Heterogeneity test was conducted on the results of the study. The I^2 test was used to analyze the heterogeneity among the results of the study within the group. If the heterogeneity test results were P ≥ 0.1 and I^2 < 50%, the fixed-effects model was selected. In contrast, if P < 0.1 or I^2 ≥ 50%, the random-effects model was used. Sensitivity analysis and subgroup analysis were conducted when the heterogeneity was significant.

RESULTS

In the present meta-analysis, 122 relevant studies were retrieved: 9 from PubMed, 39 from EMBASE, 1 from the Cochrane Library, 21 from the VIP, 33 from the CNKI and 28 from the WanFang
Yu et al. Effectiveness of PPI in COPD

FIGURE 1 | The PRISMA 2020 flow chart.

database. After screening, 15 RCTs (10–24) were identified for this meta-analysis. Overall, these studies included 1,684 patients, 806 of whom received conventional treatment (control group) and 878 of whom received conventional treatment plus PPI therapy (PPI group). The details of literature search and selection procedures are shown in Figure 1. The basic information of all patients is shown in Table 1.

Quality Assessment
As previous mentioned, we used RoB2 to assess the risk of bias and the GRADE to rate the level of evidence of the outcomes in this meta-analysis (8, 9). Risk assessment results suggested that five studies were at low risk (14, 16, 18, 20, 23), three had some concerns (10, 13, 19) and seven studies had high risk (11, 12, 15, 17, 21, 22, 24). The risk of bias for each included study is shown in Figure 2 and the GRADE evidence levels of all outcomes are shown in Table 2.

Case Fatality Rate
A total of nine studies (12, 13, 15–19, 23, 24) compared the case fatality rates between the PPI group (n = 523) and the control group (n = 450). The results of the heterogeneity test showed $I^2 = 0\%$, so the fixed-effects model was used for combined analysis. Results of the meta-analysis revealed that the case fatality rate of the PPI group can be significantly reduced compared with that of the control group (RR = 0.3; 95% CI, 0.18–0.52; P < 0.0001) (Figure 3).

Clinical Efficacy
Six studies (14, 15, 20, 22–24) reported the clinical efficacy of PPI therapy in the PPI group (n = 390) in comparison with the control group (n = 307). The heterogeneity test showed $I^2 = 59\%$. The sensitivity analysis suggested that the study conducted by Zu et al. (20) might be the source of heterogeneity. Therefore, a random-effects model analysis was used. The results of the meta-analysis presented the lack of significant difference between the two groups (RR = 1.08; 95% CI, 0.95–1.22; P = 0.25) (Figure 4).
Incidence of Gastrointestinal Bleeding

A total of 10 studies (12–14, 16–19, 23, 24) reported gastrointestinal bleeding events, including 584 and 511 cases in the PPI group and control group, respectively. The heterogeneity test showed $I^2 = 0\%$; therefore, a fixed-effects model was employed. The results of the meta-analysis revealed that the incidence of gastrointestinal bleeding can be significantly reduced in patients with COPD who received PPI ($RR = 0.23; 95\% CI, 0.14–0.38; P < 0.00001$) (Figure 5).

Incidence of Other Adverse Reactions

Eleven studies (11–19, 22, 23) reported other adverse events except gastrointestinal bleeding, including 738 and 665 cases in the PPI group and control group, respectively. The heterogeneity test showed $I^2 = 0\%$; thus, a fixed-effects model was used. Compared with conventional treatment alone, PPI therapy in patients with COPD can reduce the incidence of other adverse reactions ($RR = 0.33; 95\% CI, 0.28–0.39; P < 0.00001$) (Figure 6).
Number of Acute Exacerbations
Two studies (10, 18) reported the number of acute exacerbations, including 113 cases each in the PPI and control groups. The heterogeneity test showed $I^2 = 85\%$; therefore, a random-effects model was chosen. Compared with conventional treatment alone, PPI therapy in patients with COPD can reduce the number of acute exacerbations (MD = −1.17; 95% CI, −1.75 to −0.60; $P < 0.0001$) (Figure 7A).

FEV1/FVC
Two studies (20, 21) reported on pulmonary ventilation function, including 90 and 91 cases in the PPI group and control group, respectively. The heterogeneity test showed $I^2 = 96\%$; therefore, a random-effects model was chosen. The results of the meta-analysis showed no significant difference between the two groups (MD = 3.94; 95% CI, −8.70 to −16.58; $P = 0.54$) (Figure 7B).

Nosocomial Infection Rate
Two studies (18, 23) reported the occurrence of nosocomial infections, including 165 and 113 cases in the PPI group and control group, respectively. The heterogeneity test showed $I^2 = 0\%$; therefore, a fixed-effects model was used. The results of the meta-analysis revealed no significant difference between the two groups (RR = 1.31; 95% CI, 0.57–3.00; $P = 0.52$) (Figure 7C).
TABLE 2 | The evidence level of the outcomes obtained in this study was evaluated using GRADE.

| No of studies | Design               | Risk of bias | Inconsistency | Indirectness | Imprecision Other considerations | PPI Conventional treatment | Relative (95% CI) | Absolute | Quality | Importance |
|---------------|----------------------|--------------|---------------|--------------|----------------------------------|----------------------------|-----------------------|----------|---------|------------|
| **Case fatality rate** | 9 Randomized trials | Serious\(^a\) | No serious inconsistency | No serious indirectness | No serious imprecision Reporting bias\(^a\) | 16/523 (3.1%) | 42/450 (9.3%) RR 0.3 (0.18 to 0.52) | 65 fewer per 1,000 (from 45 fewer to 77 fewer) | ⊕ ⊕ ○○ | LOW       |
| **Clinical efficacy** | 5 Randomized trials | Serious\(^a\) | No serious inconsistency | No serious indirectness | No serious imprecision None | 290/348 (83.3%) | 213/266 (80.1%) RR 1.1 (1.02 to 1.19) | 80 more per 1,000 (from 16 more to 152 more) | ⊕ ⊕ ○○ | MODERATE  |
| **Incidence of gastrointestinal bleeding** | 10 Randomized trials | Serious\(^a\) | No serious inconsistency | No serious indirectness | No serious imprecision Reporting bias\(^a\) | 16/584 (2.7%) | 67/511 (13.1%) RR 0.23 (0.14 to 0.38) | 101 fewer per 1000 (from 81 fewer to 113 fewer) | ⊕ ⊕ ○○ | LOW       |
| **Incidence of adverse reactions** | 11 Randomized trials | Serious\(^a\) | No serious inconsistency | No serious indirectness | No serious imprecision Reporting bias\(^a\) | 122/678 (18%) | 334/635 (52.6%) RR 0.33 (0.28 to 0.39) | 352 fewer per 1000 (from 321 fewer to 379 fewer) | ⊕ ⊕ ○○ | LOW       |
| **The number of acute exacerbations (Better indicated by lower values)** | 2 Randomized trials | Serious\(^a\) | No serious indirectness | No serious imprecision None | 113 | 113 – MD 1.17 lower (1.75 to 0.6 lower) | 6.8% | ⊕ ⊕ ○○ | LOW       |
| **FEV1/FVC (Better indicated by lower values)** | 2 Randomized trials | Serious\(^a\) | No serious indirectness | No serious imprecision None | 90 | 91 – MD 3.94 higher (8.7 lower to 16.58 higher) | 6.8% | ⊕ ⊕ ○○ | LOW       |
| **Nosocomial infection rate** | 2 Randomized trials | Serious\(^a\) | No serious indirectness | Serious\(^a\) None | 17/165 (10.3%) | 7/113 (6.2%) RR 1.31 (0.57 to 3) | 19 more per 1,000 (from 27 fewer to 124 more) | ⊕ ○ ○○ | VERY LOW  |

\(^a\)means Risk of bias graph.
Publication Bias

The present study included 15 studies, of which, 13 were from China. Therefore, there may be some publication bias in this study. We used funnel plots to verify publication bias (Figure 8). The graph is not completely symmetrical, indicating some
FIGURE 6 | Forest plot of the incidence of other adverse reactions between the PPI treatment group and the conventional treatment group. PPI, proton-pump inhibitor.

FIGURE 7 | (A) Forest plot of the number of acute exacerbations between the PPI treatment and conventional treatment groups; (B) Forest plot of FEV1/FVC between the PPI treatment and conventional treatment groups; (C) Forest plot of nosocomial infection rate between the PPI treatment and conventional treatment groups. FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity; PPI, proton-pump inhibitor.
publication bias. This is also one of the limitations of the present study.

DISCUSSION

Recently, several RCTs have focused on the role of PPI in patients with COPD. A study suggested that PPI therapy was safe and feasible in patients with COPD (25). A systematic review in the Cochrane database also tried to explore the effect of PPI therapy on patients with COPD. However, this study was only at the design stage, and no specific conclusions have been drawn (26). Therefore, we conducted this meta-analysis to clarify this issue. The results of this study suggested that PPI therapy in patients with COPD can reduce the case fatality rate, occurrence of gastrointestinal bleeding, other adverse reactions and number of acute exacerbations. The findings from this study may provide some guidance for the application of PPI in patients with COPD.

The results of the present study can be attributed to the following aspects: First, patients with COPD have long-term hypoxia, the gastrointestinal tract is the most sensitive organ for ischemia and hypoxia, and there are varying degrees of gastric mucosal damage. Especially, for older people who often have atherosclerosis and long-term use of non-steroidal drugs, the risk of gastrointestinal bleeding is high (27, 28). PPI is an H+/K+-ATPase inhibitor that has a strong inhibitory effect on gastric acid secretion and a protective effect on the gastric mucosa. It can effectively prevent and treat upper gastrointestinal bleeding, promote enteral nutrition support for patients immediately, enhance immunity and reduce abdominal distension and incidence of adverse reactions, such as diarrhea (25). Second, the clinical manifestations of COPD include repeated coughing, sputum expectoration and wheezing, which are closely related to a deteriorated condition (29). PPI can reduce the irritation of gastric acid and reflux of gastric contents on the esophagus and bronchi and relieve cough, sputum production and other uncomfortable clinical manifestations. Moreover, it can reduce the incidence of minor aspiration caused by gastroesophageal reflux and avoid the occurrence of aspiration pneumonia (30). Third, previous studies have found that local or systemic inflammatory infection is an important factor for the pathogenesis of COPD, and more evidence supports the use of PPI to reduce inflammation (29–32). PPI can improve neurogenic inflammation, reduce plasma and sputum substance levels, block gastric acid secretion and selectively inhibited tumor necrosis factor-αand interleukin-1β secretion by Toll-like receptor-activated human monocytes in vitro, in the absence of toxic effects. Thus, the risk of infection in patients with COPD was reduced (1, 2). Fourth, mortality outcomes of patients with COPD are closely related to the frequency of acute exacerbations. PPI can reduce the risk of infection and the number of acute exacerbations in COPD patients, thereby reducing the risk of death. Fifth, 12 RCTs included in this study enrolled patients with acute exacerbations or even respiratory failure requiring hospitalization. Such patients have poor lung function on admission. Conventional treatments such as antibiotic therapy, nebulisation, resolving phlegm and administration of antispasmodic and anti-asthmatic drugs have contributed most to the improvement of respiratory function. Compared with conventional treatment, short-term PPI therapy during hospitalization cannot show a significant improvement in FEV1/FVC indicators. Sixth, in recent years, studies have found that the intestinal microbiota can regulate the systemic immune response, thereby affecting the function of extraintestinal organs. The gut-lung axis has received increasing attention on whether long-term PPI therapy causes bacterial overgrowth in the small intestine, bacterial peritonitis, intestinal flora shift, etc. There is currently no high-quality evidence (25, 33–35).

The preset study analyzed the effect of PPI therapy on the occurrence of nosocomial infections in patients with COPD, and tried to explore the contribution of PPI to the overall inflammatory response. However, two articles were finally included. The results were not statistically significant, and the effect of PPI therapy on the occurrence of nosocomial infections in patients with COPD has not been proved yet.

However, this study has the following limitations: First, the included studies had fewer patients with stable COPD, the study sample size was limited, and the clinical data of the population needed to be integrated to further improve the evidence. Second, most of the included studies did not report specific randomization methods and allocation concealment, and there was a greater risk of bias. Third, most of the included studies focus on Asian populations with limited geographic distribution; thus, multi-ethnic population studies are needed to provide evidence. Fourth, this meta-analysis had some publication bias. Finally, the high heterogeneity of some results may affect the reliability of these results, thus, we used a random-effects model to combine the results to make the results more reliable.

In summary, the currently available limited evidence shows that PPI therapy of patients with COPD can reduce the case fatality rate, incidence of adverse reactions including gastrointestinal bleeding and number of acute exacerbations. At present, PPI therapy is not yet recommended in COPD guidelines. PPI is mainly used in patients with digestive system...
diseases. Therefore, PPI therapy may be beneficial to patients with COPD with high-risk factors of the digestive system.

**CONCLUSION**

PPI therapy has significant effects on patients with COPD in reducing the number of acute attacks, adverse reactions, and mortality. This conclusion requires further verification in larger-scale RCTs.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

**REFERENCES**

1. López-Campos JL, Tan W, Soriano JB. Global burden of COPD. *Respirology.* (2016) 21:14–23. doi: 10.1111/resp.12660
2. Rascon-Aguilar IE, Palmer M, Whudya P, Cury J, Vega KJ. Poorly treated or unrecognized GERD reduces quality of life in patients with COPD. *Digest Dis Sci.* (2011) 56:1976–80. doi: 10.1007/s10620-010-1542-5
3. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. *Semin Respir Crit Care Med.* (2015) 36:575–91. doi: 10.1055/s-0035-1556063
4. Kostikas K, Clemens A, Patalano F. Prediction and prevention of exacerbations and mortality in patients with COPD. *Exp Rev Respir Med.* (2016) 10:739–53. doi: 10.1080/17476348.2016.1185371
5. Smith MC, Wrob J. Epidemiology and clinical impact of major comorbidities in patients with COPD. *Int J Chron Obstruct Pulmon Dis.* (2014) 9:871–88. doi: 10.2147/COPD.S49623
6. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available online at: https://goldcopd.org/goldreports/2020 (accessed February 03, 2022).
7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* (2021) 372:n71. doi: 10.1136/bmj.n71
8. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ.* (2019) 366:j4898. doi: 10.1136/bmj.j4898
9. Rasch A, Perleth M, Langer G, Meerphol JJ, Gartlehner G, Kaminski-Hartenhauer A, et al. GRADE Leitlinien: 8. Einschätzung der Qualität der Evidenz - Indirektheit [GRADE guidelines: 8. Rating the quality of evidence - indirectness]. *Z Evid Fortbild Qual Gesundwes.* (2012) 106:745–53. doi: 10.1016/j.zefq.2012.10.019
10. Sasaki T, Nakayama K, Yasuda H, Yoshida M, Asamura T, Ohnri T, et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. *J Am Geriat Soc.* (2009) 57:1453–7. doi: 10.1111/j.1532-5415.2009.02349.x
11. Huang H. Observation on the efficacy of pantoprazole in preventing gastrointestinal bleeding during acute exacerbation of respiratory failure in elderly patients with COPD. *J Health Care Today.* (2018) 9(9):2–3. doi: 10.3969/j.issn.1671-0223(s).2018.09.063
12. Wang L. Analysis of the efficacy of pantoprazole in preventing gastrointestinal hemorrhage during acute exacerbation of COPD in elderly patients. *J Clin Rational Use.* (2017) 04:105–7. doi: 10.15887/j.cnki.13-1389r.2017.04.061
13. Li W. Efficacy of pantoprazole in preventing gastrointestinal hemorrhage during acute exacerbation of respiratory failure in elderly patients with COPD. *J Dig Latest Med Inform World.* (2017) 23:77. doi: 10.3969/j.issn.1871-3141.2017.23.065
14. Xiong X. The efficacy of pantoprazole in preventing gastrointestinal bleeding during acute exacerbation of respiratory failure in elderly patients with COPD. *J Health Care Today.* (2018) 9(9):2–3. doi: 10.3969/j.issn.1671-0223(s).2018.09.063
15. Zhen H. The efficacy of pantoprazole in preventing gastrointestinal bleeding during acute exacerbation of COPD in elderly patients. *J Clin Rational Use.* (2017) 04:105–7. doi: 10.15887/j.cnki.13-1389r.2017.04.061
16. Gu Q. Efficacy of pantoprazole in preventing gastrointestinal bleeding in acute exacerbation of COPD respiratory failure in elderly patients. *J China Mod Doctor.* (2019) 57:45–8.
17. Xu Z, Jiao X. The efficacy of pantoprazole in preventing gastrointestinal bleeding during acute exacerbation of COPD in elderly patients. *World Latest Med Inform.* (2014) 36:220–1. doi: 10.3969/j.issn.1671-3141.2014.36.205
18. Hu X. The clinical research on long-term low-dose omeprazole treatment of chronic obstructive pulmonary disease in acute attack. *J China Primary Med.* (2018) 25:16. doi: 10.3760/cma.j.issn.1008-6706.2018.16.008
19. Hu L, Hua W. The effect of pantoprazole on preventing mechanical ventilation in the treatment of gastrointestinal bleeding in acute exacerbation of chronic obstructive pulmonary disease. *China Pract Med.* (2014) 17:137–8.
20. Zurapia A. Effect of proton-pump inhibitors on patients with chronic obstructive pulmonary disease and gastroesophageal reflux disease. *J Electrocardiol.* (2020) 7:1. doi: 10.3877/cma.j.issn.1009-8676.2020.01.006
21. Hai-feng Z, Ling-yun G, Shao-hua T. Proton-pump inhibitors effects on pulmonary function for acute exacerbation of chronic obstructive pulmonary disease combined gastroesophageal reflux. *J Shihum Med.* (2015) 34:603–4. doi: 10.3969/j.issn.1004-0501.2013.03.012
22. Xiao Z. Observation of the effect of pantoprazole sodium for injection in the prevention and treatment of gastrointestinal bleeding during acute exacerbation of chronic obstructive pulmonary disease with respiratory failure. *J Clin Rational Use.* (2020) 13:70–1. doi: 10.15887/j.cnki.13-1389/r.2020.17.041
23. Zhang ZQ, Wu CY, Wang ML, Niu HY, Fang B. Comparative study for clinical effect of different doses of pantoprazole on acute exacerbation of chronic obstructive pulmonary disease. *Pact J Cardiovasc Thorac.* (2018) 26:70–3. doi: 10.3969/j.issn.1008-5971.2018.09.017
24. Zhi Y, Wang Y, Song Y, Yang Y, Yang H. Comparison of the clinical efficacy of different doses of pantoprazole in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). *World Latest Med Inform Anfis.* (2019) 01:127–9. doi: 10.19613/j.cnki.1671-3141.2019.90.080
25. Lee SW, Lin CH, Lien HC, Lee TY, Yeh HZ, Chang CS. Proton-pump inhibitors did not increase risk of pneumonia in patients with chronic obstructive pulmonary disease. *J Clin Med Res.* (2014) 6:556–62. doi: 10.4103/0974-5707.137980
26. Kikuchi S, Imai H, Tani Y, Tajiri T, Watanabe N. Proton-pump inhibitors did not increase risk of pneumonia in patients with chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* (2020) 8:CD013113. doi: 10.1002/14651858.CD013113.pub2

**AUTHOR CONTRIBUTIONS**

FY and QH: conceptualization, writing, review, and editing. FY, YY, and QH: methodology. LZ and QH: supervision. LZ: project administration. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was funded by Hefei Key Discipline Construction Funding Project [No: Hefei Health Science Education (2019) No. 160] and Hefei Famous Medical Studio Funding Project [Hefei Talent (2019) No. 1].
27. Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: Impact, measurement and mechanisms. *Respirology*. (2015) 20:1160–71. doi: 10.1111/resp.12642

28. Cortopassi F, Gurung P, Pinto-Plata V. Chronic obstructive pulmonary disease in elderly patients. *Clin Geriatr Med*. (2017) 33: 539–52. doi: 10.1016/j.cger.2017.06.006

29. Contoli M, Baraldo S, Conti V, Gnesini G, Marku R, Casolari P, et al. Airway inflammatory profile is correlated with symptoms in stable COPD: a longitudinal proof-of-concept cohort study. *Respirology*. (2020) 25:80–8. doi: 10.1111/resp.13607

30. Takeda N, Takemura M, Kanemitsu Y, Hijikata H, Fukumitsu K, Asano T, et al. Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: implications of neurogenic and neutrophilic inflammation. *J Asthma*. (2020) 57:1202–10. doi: 10.1080/02770903.2019.1641204

31. Bagdonas E, Raudoniute J, Bruzauskaite I, Aldonyte R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. *Int J Chron Obstruct Pulmon Dis*. (2015) 10:995–1013. doi: 10.2147/COPD.S82518

32. Balza E, Piccioli P, Carta S, Lavieri R, Gattorno M, Semino C, et al. Proton-pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. *Cell Death Dis*. (2016) 7:e2304. doi: 10.1038/cddis.2016.218

33. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc Natl Acad Sci USA*. (2011) 108:5354–9. doi: 10.1073/pnas.1019378108

34. Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M, et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. *EMBO Rep*. (2012) 13:440–7. doi: 10.1038/embor.2012.32

35. Keir HR, Dicker A, Lonergan M, Crichton M, Miller BE, Tal-Singer R, et al. Clinical endotypes of exacerbation are associated with differences in microbial composition and diversity in COPD. *Eur Respir J*. (2020) 56:2000391. doi: 10.1183/13993003.00391-2020

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yu, Huang, Ye and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.